Empowered Funds’s ImmunityBio IBRX Stock Holding History

Empowered Funds’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$116K	Buy	13,205 +1,516	+13%	+$11.5K	﹤0.01%	2078
2026 Q1	$89.7K	Sell	11,689 -2,276	-16%	-$15.6K	﹤0.01%	2075
2025 Q4	$27.7K	Buy	+13,965	New	+$31.6K	﹤0.01%	992

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Empowered Funds's IBRX Position: Q2 2026 in Review

Empowered Funds increased its ImmunityBio (IBRX) stake by 13% in Q2 2026, buying an estimated $11.5K and bringing the position to 13,205 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #2078.

Empowered Funds first reported a position in IBRX in Q4 2025 and has held it in 3 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Empowered Funds held 13,205 shares of ImmunityBio worth $116K as of Q2 2026.
Empowered Funds bought 1,516 ImmunityBio shares in Q2 2026, an estimated $11.5K.
ImmunityBio made up ﹤0.01% of Empowered Funds's portfolio in Q2 2026, its #2078 holding.
Empowered Funds first reported a position in ImmunityBio in Q4 2025 and has held it in 3 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.